Skip to main content

Table 1 Demographic features, comorbidities, and treatment status in both HCV patients post chemotherapy (cases) and HCV patients without cancer (controls)

From: Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience

  Groups of HCV patients Total
N (%)
171(100%)
p-value
Post chemotherapy
N (%)
83 (48.5%)
Without cancer
N (%)
88 (51.5%)
Gender
 Female 44 (53%) 45 (51.1%) 89 (52%) 0.806
 Male 39 (47%) 43 (48.9%) 82 (48%)  
Age/years
Mean ± SD 52 ± 14 51 ± 13   0.660
BMI
Mean ± SD 29 ± 5 30 ± 6   0.406
Treatment status
 Treatment experienced 15 (18.1%) 13 (14.8%) 28 (16.4%) 0.560
Tobacco consumption 5 (6%) 2 (2.3%) 7 (4.1%) 0.216
Hypertension 5 (6%) 6 (6.8%) 11 (6.4%) 0.35
DM 20 (24.1%) 13 (14.8%) 33 (19.3%) 0.123